Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study

Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study

10.3390/cancers13061308

Saved in:

Bibliographic Details
Main Authors:	Lee, Pei Yi, Oen, Kellynn Qi Xuan, Lim, Grace Rui Si, JUANDA LEO HARTONO, MARK DHINESH MUTHIAH, Huang, Daniel Q, Teo, Felicia Su Wei, LI YUNKAI ANDREW, Mak, A., Chandran, Nisha Suyien, CHRIS TAN LIXIAN, Yang, Peiling, Tai, E.S., Ng, Kay Wei Ping, JOY VIJAYAN, Chan, Yee Cheun, TAN LI LING, LEE BENG HUAT, MARTIN, Chua, Horng Ruey, HONG WEI ZHEN, YAP ENG SOO, Lim, Dawn K, YUEN YEW SEN, Chan, Y.H., FOLEFAC AMINKENG, Wong, Alvin Seng Cheong, Huang, Yiqing, TAY SEN HEE
Other Authors:	MEDICINE
Format:	Article
Language:	English
Published:	MDPI 2021
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology neutrophil-to-lymphocyte ratio immunotherapy immune-related adverse events survival
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/208036
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Pharmacogenomic prediction of immune-related adverse events from immune checkpoint inhibitors among Asian patients
by: Huang, Yiqing, et al.
Published: (2022)

SILENCING XRN1 ENHANCED THE EFFECT OF IMMUNE CHECKPOINT BLOCKADE THERAPY
by: RAN XUEBIN
Published: (2022)

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
by: Xiong, Zhewen, et al.
Published: (2023)

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
by: Huang, Yiqing, et al.
Published: (2023)

Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
by: Tay, Sen Hee, et al.
Published: (2022)

Microbial synthesis of Prussian blue for potentiating checkpoint blockade immunotherapy
by: Wang, Dongdong, et al.
Published: (2023)

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
by: Sundar, Raghav, et al.
Published: (2022)

Update on immune checkpoint inhibitors in gynecological cancers
by: Heong, Valerie, et al.
Published: (2021)

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Asian Patients with Advanced NSCLC
by: Huang, Y, et al.
Published: (2023)

Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
by: Sundar, R., et al.
Published: (2021)

Immune checkpoint inhibitor in recurrent hypermutated glioblastoma with POLE mutation
by: Sith Sathornsumetee, et al.
Published: (2022)

Transcriptional regulation of cancer immune checkpoints: Emerging strategies for immunotherapy
by: Simran Venkatraman, et al.
Published: (2020)

Immune-related adverse events from immune checkpoint inhibitors: Review of risk factors in clinical practice
by: Jennis Meanwatthana
Published: (2020)

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
by: Ng K.Y.Y., et al.
Published: (2022)

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
by: Sundar, R, et al.
Published: (2019)

Targeting adenosine-2 B receptor : a potential metabolic immune checkpoint
by: Tay, Hui Min
Published: (2019)

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
by: Nuttapong Ngamphaiboon, et al.
Published: (2022)

Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint
by: Verma, Navin Kumar, et al.
Published: (2023)

Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma
by: Goggi, Julian L., et al.
Published: (2022)

Atypical response patterns in renal cell carcinoma treated with immune checkpoint inhibitors—navigating the radiologic potpourri
by: Wong, Alvin, et al.
Published: (2022)

IMMUNOTHERAPY AGAINST ADVANCED CANCERS – CHIMERIC ANTIGEN RECEPTOR-BASED APPROACH AND IMMUNE CHECKPOINT REGULATION
by: TAY CHIN KANG JOHAN
Published: (2019)

The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application
by: Huo, Jin-Ling, et al.
Published: (2022)

Granzyme B PET Imaging of Combined Chemotherapy and Immune Checkpoint Inhibitor Therapy in Colon Cancer
by: Goggi, Julian L., et al.
Published: (2022)

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
by: Ibis B.
Published: (2023)

Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
by: Huang, Yiqing, et al.
Published: (2022)

Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer
by: Mishra, Alok K., et al.
Published: (2024)

Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells
by: Fehlings, M, et al.
Published: (2020)

BHLHE40 Regulates the T-Cell Effector Function Required for Tumor Microenvironment Remodeling and Immune Checkpoint Therapy Efficacy
by: Salmon, Avery J, et al.
Published: (2023)

LOCAL IMMUNITY OF CHICKENS AGAINST NEWCASTLE DISEASE VIRUS
by: WONG TZE SEN
Published: (2020)

Checkpoint Responses in Cancer Therapy
by: Wei Dai.
Published: (2017)

Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility
by: Budi Santoso, -, et al.
Published: (2020)

Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma
by: Ngamphaiboon N.
Published: (2023)

Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model
by: Yoshimoto, Y., et al.
Published: (2016)

Garcinia mangostana L. Pericarp Extract and Its Active Compound α-Mangostin as Potential Inhibitors of Immune Checkpoint Programmed Death Ligand-1
by: Naing S.
Published: (2023)

Checkpoint
by: Ang, Tiffany Si Ying, et al.
Published: (2008)

Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors
by: Suntiparpluacha M.
Published: (2023)

A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians
by: Peng, S., et al.
Published: (2021)

Prolonged Survival and Preserved Renal Graft Function in a Kidney Transplant Patient With Advanced Urothelial Carcinoma Using an Immune Checkpoint Inhibitor: A Case Report
by: Mavichak W.
Published: (2023)

Transfer rate of transplacental immunity to tetanus from non-immunized and immunized mothers
by: V. Sangpetchsong, et al.
Published: (2018)

Label-Free Biophysical Markers from Whole Blood Microfluidic Immune Profiling Reveal Severe Immune Response Signatures
by: Zeming, Kerwin Kwek, et al.
Published: (2021)